|
KMID : 1009020170150020126
|
|
Clinical Psychopharmacology and Neuroscience
2017 Volume.15 No. 2 p.126 ~ p.131
|
|
|
Effects of Escitalopram on Anxiety in Patients with Acute Coronary Syndrome: A Randomized Controlled Trial
|
|
Kang Hee-Ju
Bae Kyung-Yeol
Kim Sung-Wan
Shin Il-Seon
Hong Young-Joon
Ahn Young-Keun
Jeong Myung-Ho
Yoon Jin-Sang
Kim Jae-Min
|
|
|
Abstract
|
|
|
Objective: There are no evidence-based practices for treating anxiety in patients with acute coronary syndrome (ACS). Thus, we investigated the effects of escitalopram on anxiety in this population.
Methods: We enrolled 217 patients with ACS who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for depressive disorders into a randomized double-blind placebo-controlled study. Patients received either escitalopram or placebo over a 24-week period. Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A). A HADS-A score >7 was classified as an anxiety disorder. Baseline evaluations included sociodemographic and clinical characteristics, such as depressive symptoms, cardiovascular risk factors, and current cardiac status.
Results: Independent of improvements in depression and without any differences in safety profiles, escitalopram treatment was significantly more efficacious in treating and reducing anxiety than placebo over a 24-week period.
Conclusion: Escitalopram can be recommended as an effective and safe treatment option for anxiety in patients with ACS.
|
|
|
KEYWORD
|
|
|
Acute coronary syndrome, Anxiety, Depression, Escitalopram, Double-blind study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|